Trial reportBMC pregnancy and childbirth2026
Postpartum readmission for maternal infection or neonatal adverse events in women randomised to outpatient balloon versus inpatient prostaglandin for induction of labour: a post-trial follow up study.
Trial report in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInduction of labour is common, and much has been studied about different methods and clinical outcomes for mothers and babies. However, many trials follow outcomes only until hospital discharge. The recently published OBLIGE multicentre randomised controlled trial of 1087 participants found no differences in adverse events for mothers or their babies in groups randomised at term to outpatient balloon catheter versus inpatient vaginal prostaglandin E2. The aim of this analysis was to evaluate maternal and neonatal readmissions from hospital discharge to six weeks after birth.
methodsA post-trial follow up of the OBLIGE trial. The clinical records of a subset of participants for whom notes were accessible were reviewed (564 mothers and 477 babies). The primary outcome was maternal readmission to hospital up to six weeks after birth (including a hospital visit of 3 h or more) for infection requiring antibiotics. The secondary outcome was neonatal readmission to hospital up to six weeks after birth (including a hospital visit of 3 h or more) for any reason.
resultsOf women randomised to outpatient balloon, 6.3% were readmitted with an infection compared to 6.5% in the inpatient prostaglandin group (p = 0.99). Of babies born to mothers randomised to outpatient balloon, 10.2% were readmitted compared to 11.7% in the inpatient prostaglandin group (p = 0.59).
conclusionsIn this subset of participants in the OBLIGE trial, there were no differences in maternal readmission for infection, or neonatal admission for any reason, up to six weeks after birth. Consideration of readmission risk for mothers and babies after outpatient balloon induction of labour does not seem to be a reason not to routinely offer outpatient balloon induction of labour.
trial registrationThe OBLIGE trial was registered with the Australia New Zealand Clinical Trials Registry (ANZCTR) on 06/06/2016 (ACTRN: 12,616,000,739,415). https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=370330&isReview=true
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.